AMENDMENT TO THE CLAIMS

This claim listing will replace all prior versions, and listings, of the claims in the application.

1. (Cancelled) A compound comprising 8 to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence specifically hybridizable with a nucleic acid encoding a B7 protein and said compound modulates the expression of said B7 protein.

2. (Cancelled) The compound of claim 1 which is an antisense oligonucleotide.

3. (Cancelled) The compound of claim 1, wherein at least one of said covalent linkages is a modified covalent linkage.

4. (Cancelled) The compound of claim 1, wherein at least one of said nucleotides has a modified sugar moiety.

5. (Cancelled) The compound of claim 4, wherein said modified sugar moiety is a modification at the 2' position of any nucleotide, the 3' position of the 3' terminal nucleotide or the 5' position of the 5' terminal oligonucleotide.

6. (Cancelled) The compound of claim 1, wherein at least one of said nucleotides has a modified nucleobase.

7. (Cancelled) The compound of claim 1, wherein said oligonucleotide comprises at least one lipophilic moiety which enhances the cellular uptake of said oligonucleotide.

8. (Cancelled) The compound of claim 1 wherein said B7 protein is human B7-1.

9. (Cancelled) The compound of claim 8 wherein said sequence comprises SEQ ID NO: 228, 231, 234, 235, 237, 238, 240, 241, 243, 247, 248, 250 or 241.

10. (Cancelled) The compound of claim 1 wherein said B7 protein is human B7-2.

11. (Cancelled) The compound of claim 10 wherein said sequence comprises SEQ ID NO: 256, 257, 259, 263, 267, 269, 270, 271, 272, 273, 274, 275, 278, 280, 282, 283, 284 or 285.

12. (Cancelled) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

13. (Cancelled) The composition of claim 12 further comprising an anti-inflammatory or immunosuppressive agent.

14. (Cancelled) A composition comprising:

(a) the compound of claim 8;

(b) the compound of claim 10 and

(c) a pharmaceutically acceptable carrier.

15. (Cancelled) The composition of claim 14 further comprising an anti-inflammatory or immunosuppressive agent.

16. (Cancelled) A method of modulating the expression of a B7 protein in cells or tissues comprising contacting said cells or tissues with a compound of claim 1.

17. (Cancelled) The method of claim 16 wherein said cells or tissues are antigen presenting cells.

18. (Cancelled) A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a compound of claim 1.

19. (Cancelled) The method of claim 18 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

20. (Cancelled) A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a composition of claim 12.

21. (Cancelled) The method of claim 20 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

22. (Cancelled) A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a composition of claim 14.

23. (Cancelled) The method of claim 22 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.

24. (Cancelled) A method of inhibiting a T cell response in antigen-presenting cells comprising contacting antigen presenting cells with a compound of claim 1.

25. (Cancelled) A method of inhibiting allograft rejection in an animal comprising administering to said animal a compound of claim 1.

26. (Cancelled) A method of inhibiting allograft rejection in an animal comprising administering to an animal an anti-inflammatory or immunosuppressive agent and a compound of claim 1.

27. (Cancelled) A method of inhibiting allograft rejection in an animal comprising administering to the animal the composition of claim 12.

28. (Cancelled) The method of claim 27 further comprising administering to the animal an anti-inflammatory or immunosuppressive agent.

29. (Cancelled) A method of inhibiting allograft rejection in an animal comprising administering to the animal the composition of claim 14.

30. (Cancelled) The method of claim 29 further comprising administering to the animal an anti-inflammatory or immunosuppressive agent.

31. (New) An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human B7, said compound comprising at least an 8-nucleobase portion of SEQ ID NO: 256.

32. (New) The antisense compound of claim 31 which is an antisense oligonucleotide.

33. (New) The antisense compound of claim 32 which is modified.

34. (New) The antisense compound of claim 31 which is between 18 and 30 nucleobases in length.

35. (New) The antisense compound of claim 31 comprising SEQ ID NO: 256.

36. (New) The antisense compound of claim 32 which comprises at least one modified internucleoside linkage.

37. (New) The antisense compound of claim 36 wherein the modified internucleoside linkage is a phosphorothioate linkage.

38. (New) The antisense compound of claim 37 wherein every internucleoside linkage is a phosphorothioate linkage.

39. (New) The antisense compound of claim 32 which comprises at least one modified sugar moiety.

40. (New) The antisense compound of claim 39 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

41. (New) The antisense compound of claim 32 which comprises at least one modified nucleobase.

42. (New) The antisense compound of claim 41 wherein the modified nucleobase is a 5-methylcytosine.

43. (New) The antisense compound of claim 41 wherein nucleobases 1-4 and 15-18 comprise a 2'-O-methoxyethyl modification.

44. (New) The antisense compound of claim 41, wherein each cytidine residue comprises a 5-methyl modification.

45. (New) The antisense compound of claim 31, that is a pharmaceutically acceptable salt.

46. (New) The antisense compound of claim 45 that is a sodium salt.

47. (New) A composition comprising the antisense compound of claim 31 in combination with a carrier or diluent.

48. (New) The composition of claim 47 further comprising a colloidal dispersion system.

49. (New) The composition of claim 47 further comprising an anti-inflammatory or immunosuppressive agent.

50. (New) A composition comprising an antisense compound consisting of SEQ ID NO: 256.

51. (New) The composition of claim 50, wherein every internucleoside linkage of the antisense compound is a phosphorothioate linkage.

52. (New) The composition of claim 50, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

53. (New) The composition of claim 50, wherein the antisense compound is a pharmaceutically acceptable salt.

54. (New) The composition of claim 53 wherein the pharmaceutically acceptable salt is a sodium salt.

55. (New) The composition of claim 50 further comprising a pharmaceutically acceptable carrier or diluent.

56. (New) The composition of claim 53 further comprising a pharmaceutically acceptable carrier or diluent.

57. (New) A composition comprising an antisense compound comprising SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 1-4 and 15-18 comprise a 2'-O-methoxyethyl modification.

58. (New) The composition of claim 57, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

59. (New) The composition of claim 58, wherein the antisense compound is a pharmaceutically acceptable salt.

60. (New) The composition of claim 59, wherein the pharmaceutically acceptable salt is a sodium salt.

61. (New) The composition of claim 57, further comprising a pharmaceutically acceptable carrier or diluent.

62. (New) The composition of claim 61 further comprising a pharmaceutically acceptable carrier or diluent.

63. (New) A composition comprising an antisense compound consisting of SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, and nucleobases 1-4 and 15-18 comprise a 2'-O-methoxyethyl modification.

64. (New) The composition of claim 63, wherein each cytidine residue of the antisense compound comprises a 5-methyl modification.

65. (New) The composition of claim 64, wherein the antisense compound is a pharmaceutically acceptable salt.

66. (New) The composition of claim 65, wherein the pharmaceutically acceptable salt is a sodium salt.

67. (New) The composition of claim 63, further comprising a pharmaceutically acceptable carrier or diluent.

68. (New) The composition of claim 65, further comprising a pharmaceutically acceptable carrier or diluent.

69. (New) A composition comprising an antisense compound consisting of SEQ ID NO: 256, wherein every internucleoside linkage is a phosphorothioate linkage, nucleobases 1-4 and 15-18 comprise a 2'-O-methoxyethyl modification, and cytidine residues at positions 5 and 10 comprise a 5-methyl modification.

70. (New) The composition of claim 69, wherein each cytidine residue of the compound comprises a 5-methyl modification.

71. (New) The composition of claim 69, wherein the compound is a pharmaceutically acceptable salt.

72. (New) The composition of claim 71, wherein the pharmaceutically acceptable salt is a sodium salt.

73. (New) The composition of claim 69, further comprising a pharmaceutically acceptable carrier or diluent.

74. (New) The composition of claim 71, further comprising a pharmaceutically acceptable carrier or diluent.